Objective: Mortality from primary and secondary adrenal insufficiency (AI; PAI and SAI, respectively) is 2-3-fold higher than in the general population. Mortality relates to cardiovascular disease, acute adrenal crisis (AC), cancer and infections; however, there has been little further characterization of patients who have died.
| INTRODUC TI ON
If left untreated, adrenal insufficiency (AI) leads to premature death. 1 Introduction of glucocorticoid replacement therapy in patients with AI has led to greatly improved outcomes; 2 however, it is increasingly recognized that patients with AI continue to experience high levels of morbidity and premature mortality. These adverse outcomes are thought to be due to inappropriate glucocorticoid dosage and the nonphysiological nature of conventional replacement therapy. [3] [4] [5] This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Hospital record data suggest that mortality associated with primary AI (PAI) is 2-3-fold higher than in the general population. 6 In the Swedish Hospital Registry, the cardiovascular mortality associated with PAI was approximately 2-fold higher, and the mortality owing to infectious disease was approximately 6-fold higher, than that of the normal population. 6 Data from the Norwegian Hospital
Registry showed that, between 1943 and 2005, the mortality for PAI related mainly to cardiovascular disease, followed by Addisonian crisis, cancer, infection and sudden death. 7 More recently, the Swedish National Inpatient Register showed a dramatically reduced survival probability for patients with PAI and comorbid diabetes mellitus, compared with patients with diabetes mellitus alone. Cardiovascular disease and complications of diabetes mellitus were the most common causes of death. who are undergoing long-term treatment with modified-release hydrocortisone or other glucocorticoid replacement therapies.
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The primary objective of the EU-AIR is to monitor the safety of long-term treatment with once-daily, modified-release hydrocortisone and other glucocorticoid replacement therapies in patients with AI.
All enrolled patients provided written informed consent/assent.
The study protocol was approved by the appropriate ethical committee in each country. Data were collected from endocrinology centres in Germany, the Netherlands, Sweden and the UK. All enrolled patients were followed up during the course of routine clinical practice for the active duration of the registry. All medical care decisions, including those relating to treatment choice, were entirely at the discretion of the patient and registry physician. Patient data, including laboratory assessments, were collected by means of an electronic case report form at enrolment and thereafter at routine clinic visits (every 6-12 months). 14, 15 Recruitment commenced in August 2012. Patients with CAH were excluded from this analysis. Patients who withdrew consent (n = 130) and who were lost to follow-up (n = 6) were excluded.
As of June 2017, in total, 2034 patients with PAI (n = 801) and SAI (n = 1233) had been enrolled and were included in the analysis. For all included patients, follow-up data and status (deceased or alive)
were available.
Exposure records with a duration of less than 28 days were excluded to ensure that treatment at baseline was not related to emergency/temporary use of medication.
Patients were grouped according to the cause of AI (PAI or SAI), and whether they had died or were still alive at the data cut-off point 
| Statistics
Descriptive statistics (number of observations [N], mean, standard deviation, median, minimum, maximum and 95% confidence interval
[CI] for continuous variables; incidence, percentage and 95% CI for categorical variables) were provided for the cohort of patients who had died and for the cohort of those who remained alive. Inferential comparisons were not planned; values of P ≤ .05 indicated trends rather than tested hypotheses.
| RE SULTS
From August 2012 until June 2017, 26 deaths occurred (8 PAI, 18 SAI) in patients enrolled in EU-AIR, resulting in a mortality of 1.0%
for PAI and 1.5% for SAI. The main causes of death were cardiovascular disease (35%), infection (15%) and suicide (8%). However, for 19% of patients, the cause of death was not clear owing to the lack of documentation in the database (Table 1) .
Analysis of the underlying AI aetiology for the 26 deceased patients (Table 2 ) demonstrated that the subgroup of patients with PAI who had died was very specific, with 6 of 8 patients having had bilateral adrenalectomy for uncontrolled Cushing′s disease (n = 3: ♀ 77 years, ♀ 64 years, ♂ 52 years) or metastatic renal cell carcinoma (n = 3: ♀ 81 years, ♂ 77 years, ♂ 55 years). Only 2 of 8 of the patients with PAI who had died had autoimmune PAI (♀ 70 years, ♂ 45 years); their causes of death were stroke and unknown cause, respectively.
The time between bilateral adrenalectomy and death in patients having had bilateral adrenalectomy for uncontrolled Cushing′s disease was 1.5, 9.5 and 39.5 years, and causes of death were increased intracranial pressure due to sinus thrombosis, cardiac arrhythmia and unknown cause, respectively. In patients with bilateral adrenalectomy for metastatic renal cell cancer, the cause of death was probably related to their malignancy in 2 of 3 patients (renal failure; pneumonia with underlying pulmonary metastasis). Our deceased PAI cohort therefore appears to be biased towards severely sick patients with devastating underlying disease, and we do not feel that this cohort is truly representative of patients whose primary disease is directed at the adrenal gland. These data must therefore be interpreted with caution. The fact that the primary disease may have been fundamentally more important in the deceased PAI cohort is supported by the lower number of AEs and ACs, compared with the cohort of patients with PAI who remained alive (Table 3 ). In the cohort of alive patients with PAI, the frequency of AC was 7.94 per 100 patient-years ( Table 3 ).
The underlying aetiology for AI in the patients with SAI who died (Table 2) represents the common causes of SAI observed within specialized endocrine centres. In the cohort of patients with SAI who died, we observed a tendency towards more AEs and a significantly higher number of ACs compared with the SAI cohort who remained alive (Table 3 ).
In general, at baseline, patients who died were older than the average age of those who remained alive (PAI, 65. Heart failure, arrhythmia 7
Stroke 1
Sinus thrombosis 1
Unclear (general physical health deterioration) 5
Infection 4
Gastroenteritis 2
Fever 1
Pneumonia 1
Suicide 2
Toxic drug hepatitis 2
Brain tumour 1
Acute adrenal crisis 1
Renal failure 1
Cachexia 1 TA B L E 2 Underlying causes of AI in deceased patients with AI; data from the European Adrenal Insufficiency Registry
Primary AI N = 8
Bilateral adrenalectomy due to pituitary Cushing′s disease 3
Bilateral adrenalectomy due to metastatic renal cell carcinoma 3
Autoimmune primary AI 2

Secondary AI N = 18
Panhypopituitarism due to: 7
Empty sellae, Sheehan′s syndrome 2
Pituitary surgery for adenoma 3
Pituitary surgery for craniopharyngioma 1 meningioma 1
Panhypopituitarism and diabetes insipidus due to: 3
Pituitary surgery for adenoma 1
Pituitary surgery for craniopharyngioma 1
Pituitary surgery for pineal germinoma 1
Of unknown origin 5
Due to exogenous glucocorticoids 3 AI, adrenal insufficiency.
remained alive (both PAI and SAI cohorts). HbA 1c levels were higher in the patients with PAI who died than in those who remained alive (6.7 ± 0.6% vs 5.7 ± 0.9%, P = .01); however, no difference was observed in the SAI cohorts (deceased vs living: 6.2 ± 1.3% vs 5.6 ± 0.8%, P = .16).
In the SAI cohort, patients who died were predominantly male (77.8% vs 51.5%, P = .0269), whereas no difference was observed in the PAI cohort. Importantly, patients with SAI who died had been on higher daily doses of hydrocortisone (24.0 ± 7.6 vs 19.3 ± 5.7 mg, P = .002), but showed no significant differences regarding the use of dehydroepiandrosterone replacement or statins (Table 4 ). There was no significant difference in medication usage (L-thyroxine, sex hormone replacement or growth hormone replacement) between patients who died and those who remained alive (Table 4) . DHEA, dehydroepiandrosterone; MR-HC, modified-release hydrocortisone; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; SD, standard deviation. a Some patients took glucocorticoid combinations, therefore, the sum can be more than 100%.
TA B L E 3 Frequency of adverse events and adrenal crises in patients with PAI and SAI who died or remained alive
Data given as mean ± SD, median (range) for continuous variables, and percentage for categorical variables.
| D ISCUSS I ON
This is the first prospective study investigating causes of death in patients with AI. The major cause of death was cardiovascular disease, confirming hospital registry data from Norway for patients with PAI. 7 The second most frequent cause was unclear (general physical health deterioration), raising the question that an illness with an inappropriately low or zero adaptation of glucocorticoid medication might have led to this. In the Norwegian Hospital Registry, "sudden death" was the fifth most frequent cause of death for patients with PAI. 7 One of the major causes of death in our study was infection (15%), whereas
Addisonian crisis was only documented once. This is consistent with recent data which showed impaired immune function in patients with AI. 16 From a clinical point of view, and including the evidence that there is a "point of no return" with some AC, it appears to be appropriate to combine these 2 causes together, which would result in AC/ infections being the cause of death in 19.2% of patients with AI. Of particular note, however, are the 2 suicides. This observation is endorsed by a recent study which showed suicide to account for 10% of all causes of death in patients with CAH. 17 This raises the question of patient concern over the implications of their disease, 18 which might not have been adequately addressed by medical personnel.
Our data show that it is very important to analyse the underlying aetiology of AI. In our cohort of patients with PAI who died, those that remained alive. Therefore, we believe that our cohort of patients with SAI, which consisted mainly of male, older individuals who had a higher prevalence of hypertension and diabetes mellitus, is a high-risk group which deserves further attention and care. We suggest that the significantly higher, daily hydrocortisone dose in this cohort reflects the response of the treating physician to increase the hydrocortisone dosage when these patients have repeated AEs and ACs on standard, low doses of glucocorticoid therapy.
Interestingly, a recently published study based on a national inpatient database in Japan revealed that patients with SAI and AC were admitted to the intensive care unit more frequently and received extracellular fluid resuscitation, insulin therapy and catecholamines at a higher frequency than patients with PAI and AC. 25 The authors concluded that older patients with impaired consciousness and diabetes mellitus had a higher risk of death from AC.
It has been suggested that older patients with AI might have psychological and cognitive difficulties that impair self-management of their AI, especially the use of stress doses 26 and parenteral administration of hydrocortisone in emergency situations. Social isolation, which is more frequent in older age groups, might also play a role.
Additionally, older patients often show no typical symptoms of infectious disease, such as fever, and thereby delay self-management of the necessary hydrocortisone dose increases or delay approaching emergency medical personnel for parenteral application of glucocorticoids.
It is important to emphasize that our study is not representative of all European AI patients but of European AI patients who are treated in specialized centres with highly specialized care (eg, regular patient teaching sessions are common), and a high proportion of rare cases (eg, bilateral adrenalectomized Morbus Cushing patients).
We cannot rule out a certain selection bias in our study due to the fact that follow-up information was not available for patients who withdrew consent (n = 130) and those patients were not included in our cohort. Also, we cannot exclude death in patients who have been lost to follow-up (n = 6), and who similarly were not included in the analysis.
In conclusion, we have shown for the first time, the characteristics of patients with AI who have died. We identified older, male patients with SAI, who also have hypertension and diabetes mellitus as comorbidities, as having a high frequency of AC and a high mortality risk. We conclude that this high-risk group deserves further attention and increased care.
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